I evaluate emerging biotech platforms and therapeutic technologies under uncertainty, with a focus on platform credibility, technical risk, feasibility, differentiation, and strategic relevance. My work translates complex scientific and technical questions into decision-relevant insight for early R&D, strategy, and asset-evaluation contexts.